Novo Nordisk makes a bold $9B bid to acquire Metsera, a U.S. biotech firm, in a bid to outpace Pfizer's existing $4.9B deal and regain leadership in the competitive obesity drug market.
Novo Nordisk makes a bold $9B bid to acquire Metsera, a U.S. biotech firm, in a bid to outpace Pfizer's existing $4.9B deal and regain leadership in the competitive obesity drug market.
